Fraunhofer Institute for Cell Therapy and Immunology IZIIn vivo pharmacology
Fraunhofer IZI research project nominated for "HUGO JUNKERS PRIZE for Research and Innovation from Saxony-Anhalt"
The Fraunhofer Institute for Cell Therapy and Immunology IZI conducts research on neurodegenerative and inflammatory diseases at its Halle (Saale) site. With their approach of using endogenous retroviruses as target structures for new therapies against neurological diseases, the scientists qualified for the finals of this year's HUGO JUNKERS AWARD in the category "Most Innovative Basic Research Projects".
Cooperation between Fraunhofer IZI and Lipocalyx GmbH to develop new carrier systems for the genebased treatment of inflammatory diseases
The Department of Drug Design and Target Validation at the Fraunhofer IZI is being awarded a €400,000 grant from the State of Saxony-Anhalt to develop new carrier systems for the gene-based treatment of inflammatory diseases. The project will be conducted in close collaboration with Lipocalyx GmbH based in Halle.
New Humanized Mouse Models Expected to Offer Greater Insights into Alzheimer’s Disease
Alzheimer’s disease is a neurodegenerative disorder that would not normally affect mice in their natural habitat. Despite this, the animals are indispensable when it comes to Alzheimer’s research. Novel mouse models are required to more clearly display the complex interactions and relations involved in Alzheimer’s disease; models that would lead to a better understanding of the causes and progression of the disease and – it is hoped – that would facilitate the development of promising therapies and would enable the disease to be diagnosed as early as possible. Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI have now taken an important step forward in creating more appropriate mouse models. At the beginning of November, the team from Halle (Saale), Germany, attended the Society for Neuroscience’s annual meeting, where they presented for the very first time their latest advances in the development of new animal models, addressing a wide scientific audience.